Citius Pharmaceuticals, Inc.

NasdaqCM:CTXR Stock Report

Market Cap: US$62.7m

Citius Pharmaceuticals Valuation

Is CTXR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CTXR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CTXR ($0.38) is trading below our estimate of fair value ($8.43)

Significantly Below Fair Value: CTXR is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CTXR?

Other financial metrics that can be useful for relative valuation.

CTXR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-1.1x
PEG Ration/a

Price to Book Ratio vs Peers

How does CTXR's PB Ratio compare to its peers?

The above table shows the PB ratio for CTXR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.8x
ZYNE Zynerba Pharmaceuticals
2.3x67.2%US$65.6m
NTRB Nutriband
5xn/aUS$62.7m
MRMD MariMed
0.8xn/aUS$57.3m
LABP Landos Biopharma
3.1x-37.1%US$71.7m
CTXR Citius Pharmaceuticals
0.8x49.9%US$62.7m

Price-To-Book vs Peers: CTXR is good value based on its Price-To-Book Ratio (0.8x) compared to the peer average (2.9x).


Price to Earnings Ratio vs Industry

How does CTXR's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.6%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.6%
n/an/an/a
No more companies

Price-To-Book vs Industry: CTXR is good value based on its Price-To-Book Ratio (0.8x) compared to the US Pharmaceuticals industry average (1.6x).


Price to Book Ratio vs Fair Ratio

What is CTXR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CTXR PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CTXR's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CTXR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.38
US$4.67
+1,121.0%
20.2%US$6.00US$4.00n/a3
Nov ’25US$0.36
US$4.67
+1,200.3%
20.2%US$6.00US$4.00n/a3
Oct ’25US$0.47
US$4.67
+896.9%
20.2%US$6.00US$4.00n/a3
Sep ’25US$0.57
US$4.67
+718.7%
20.2%US$6.00US$4.00n/a3
Aug ’25US$0.91
US$4.67
+415.4%
20.2%US$6.00US$4.00n/a3
Feb ’25US$0.64
US$3.17
+397.3%
37.2%US$4.00US$1.50n/a3
Jan ’25US$0.76
US$2.75
+263.5%
45.5%US$4.00US$1.50n/a2
Dec ’24US$0.77
US$3.17
+309.7%
37.2%US$4.00US$1.50n/a3
Nov ’24US$0.77
US$3.17
+311.3%
37.2%US$4.00US$1.50US$0.363
Oct ’24US$0.68
US$3.17
+362.7%
37.2%US$4.00US$1.50US$0.473
Sep ’24US$0.93
US$3.17
+240.1%
37.2%US$4.00US$1.50US$0.573
Aug ’24US$0.95
US$3.17
+231.7%
37.2%US$4.00US$1.50US$0.913
Jul ’24US$1.20
US$3.83
+219.4%
48.0%US$6.00US$1.50US$0.543
Jun ’24US$1.24
US$3.83
+209.1%
48.0%US$6.00US$1.50US$0.703
May ’24US$1.50
US$3.83
+155.6%
48.0%US$6.00US$1.50US$0.733
Apr ’24US$1.17
US$5.00
+327.4%
20.0%US$6.00US$4.00US$1.032
Feb ’24US$1.41
US$3.60
+155.3%
11.1%US$4.00US$3.20US$0.642
Jan ’24US$0.79
US$3.60
+355.7%
11.1%US$4.00US$3.20US$0.762
Dec ’23US$1.23
US$3.60
+192.7%
11.1%US$4.00US$3.20US$0.772
Nov ’23US$1.07
US$4.40
+311.2%
26.8%US$6.00US$3.20US$0.773

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies